Your browser doesn't support javascript.
loading
Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes.
Yaron, Marianna; Roitman, Eytan; Aharon-Hananel, Genya; Landau, Zohar; Ganz, Tali; Yanuv, Ilan; Rozenberg, Aliza; Karp, Moshe; Ish-Shalom, Maya; Singer, Joelle; Wainstein, Julio; Raz, Itamar.
Afiliación
  • Yaron M; Diabetes Medical Center, Tel Aviv, Israel.
  • Roitman E; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Aharon-Hananel G; Diabetes Medical Center, Tel Aviv, Israel.
  • Landau Z; Diabetes Medical Center, Tel Aviv, Israel.
  • Ganz T; Diabetes Medical Center, Tel Aviv, Israel.
  • Yanuv I; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Rozenberg A; Diabetes Unit, E. Wolfson Medical Center, Holon, Israel.
  • Karp M; Diabetes Unit, E. Wolfson Medical Center, Holon, Israel.
  • Ish-Shalom M; Hebrew University, Jerusalem, Israel.
  • Singer J; Hebrew University, Jerusalem, Israel.
  • Wainstein J; Diabetes Medical Center, Tel Aviv, Israel.
  • Raz I; Diabetes Medical Center, Tel Aviv, Israel.
Diabetes Care ; 42(7): 1178-1184, 2019 07.
Article en En | MEDLINE | ID: mdl-31036546
OBJECTIVE: To assess treatment satisfaction and the effectiveness of a flash glucose monitoring (FGM) system in patients with type 2 diabetes using insulin. RESEARCH DESIGN AND METHODS: A total of 101 patients with type 2 diabetes on multiple daily insulin injections (MDI) for at least 1 year were assigned randomly to the FGM intervention (n = 53) or the standard care (control) group (n = 48) and followed for 10 weeks. Both groups were instructed to adjust their insulin doses in face-to-face and telephone visits. Satisfaction with treatment, quality of life, comfort using FGM, HbA1c, and frequency of hypoglycemic events were evaluated. RESULTS: The intervention group found treatment significantly more flexible (P = 0.019) and would recommend it to their counterparts (P = 0.023). Satisfaction using the FGM system was high. The changes in HbA1c were -0.82% (9 mmol/mol) vs. -0.33% (3.6 mmol/mol) in the intervention and control group, respectively (P = 0.005); in nonprespecified post hoc analysis, 68.6% of the patients in the intervention group had their HbA1c reduced by ≥0.5% (5.5 mmol/mol) compared with 30.2% in the control group (P < 0.001), and 39.2% had their HbA1c reduced by ≥1.0% (10.9 mmol/mol) vs. 18.6% in the control group (P = 0.0023) without an increased frequency of hypoglycemia. CONCLUSIONS: FGM tends to improve treatment satisfaction and may lead to amelioration of glycemic control in patients with type 2 diabetes on MDI without increasing the frequency of hypoglycemia.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_cobertura_universal / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Satisfacción del Paciente / Diabetes Mellitus Tipo 2 / Equipos y Suministros / Hipoglucemiantes / Insulina Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Diabetes Care Año: 2019 Tipo del documento: Article País de afiliación: Israel

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_cobertura_universal / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Satisfacción del Paciente / Diabetes Mellitus Tipo 2 / Equipos y Suministros / Hipoglucemiantes / Insulina Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Diabetes Care Año: 2019 Tipo del documento: Article País de afiliación: Israel
...